Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 6Colorectal Neoplasms 3Brain Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Stomach Neoplasms 1Metastatic Breast Cancer With a Isolated Brain Progression 1HER2-positive Metastatic Breast Cancer 1HER2-positive Gastric Cancer 1HER2-positive Breast Cancer 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Anatomic Stage II Breast Cancer AJCC v8 1Anatomic Stage IA Breast Cancer AJCC v8 1Adenocarcinoma Of Esophagus 1

Interventions

Gemcitabine 7Cisplatin 6durvalumab 5pembrolizumab 4gemcitabine-oxaliplatin regimen 3S 1 (combination) 3Carboplatin 3Trastuzumab 2Paclitaxel 2Capecitabine 2tucatinib 1tremelimumab 1merestinib 1irinotecan sucrosofate 1envafolimab 1Tegafur 1Ramucirumab 1Radiation 1Psilocybin 1Poly(ADP-ribose) Polymerase Inhibitors 1Pemetrexed 1Oxaliplatin 1Nivolumab 1Leucovorin 1Itraconazole 1Immune Checkpoint Inhibitors 1High-Throughput Nucleotide Sequencing 1Fulvestrant 1Fluorouracil 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Biliary Tract Neoplasms × tucatinib × Clear all
NCT04579380 2025-12-19

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Seagen Inc.

Phase 2 Active not recruiting
217 enrolled 19 charts
BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡